WuXi Biologics (Cayman) Inc. - ADR (WXXWY)
WuXi Biologics (Cayman) Inc. (WXXWY) Q4 2025 Earnings Call Transcript
WuXi Biologics (Cayman) Inc. (WXXWY) Q4 2025 Earnings Call Transcript
WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
WuXi Biologics: Spotlight On Property Disposal And Operating Metrics (Rating Upgrade)
My rating upgrade for WuXi Biologics to a Buy has taken into consideration its latest corporate move and business disclosures. The sale of its European manufacturing facility will throw up margin improvement and capital allocation opportunities for WXXWY. The company has secured new projects and new customers from markets outside its home market despite geopolitical concerns.
WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2024 Earnings Call Transcript
WuXi Biologics (Cayman) Inc. (OTCPK:WXXWY) Q2 2024 Earnings Conference Call August 22, 2024 8:30 AM ET Company Participants Lina Fan - Senior Vice President, Head of Investor Relations Chris Chen - Chief Executive Officer Ming Tu - Chief Financial Officer, Executive Vice President Ziyi Chen - China Healthcare Analyst, Goldman Sachs Conference Call Participants Chen Chen - UBS Samuel Isaly - Exome Asset Management Jingyi Li - Harding Loevner Ziyi Chen Great. Good morning and good evening, global investors.
